It is our pleasure to announce Gary Starling, PhD, Assoc. VP, and Merck as the winner of DANS Excellence Clinical Development Award in regards to KEYTRUDA. Dr. Starling’s career has been focused on the discovery and early development of biologic therapeutics. He held key positions at Bristol-Myers Squibb, CuraGen, PDL BioPharma, Facet Biotech (acquired by Abbott Labs) and Merck. He heads the Protein Science Department at Merck that drives the discovery of Biologics for all of Merck’s disease areas including Immuno-Oncology. Join us in congratulating Merck and Dr. Starling on this wonderful recognition.